Bendazac

Bendazac (CAS No.: 20187-55-7) is a synthetic small molecule in the arylacetic acid class that is primarily categorized as a pharmacological research tool for inflammation associated biology and lens protein homeostasis, with historical use in nonclinical studies of cataract related protein damage and broader stress induced protein destabilization processes; current evidence indicates that its central mechanism is not a single high affinity receptor interaction but a physicochemical and biochemical modulation of protein denaturation and aggregation, supporting investigation of proteostasis preserving effects under oxidative and inflammatory challenge conditions, while additional literature descriptions suggest anti inflammatory and anti allergic associated phenotypes that are generally interpreted as downstream functional outcomes rather than definitively mapped target specific signaling events, and therefore its pathway assignment is typically framed at the level of inflammation linked stress response networks and protein quality control biology rather than a validated canonical node; consistent with this profile, publicly summarized data for this molecule do not provide a robust consensus set of target resolved potency constants such as IC50 or EC50 across standardized panels, so activity is generally handled in exploratory concentration response designs that often span low micromolar to higher micromolar ranges depending on matrix, endpoint, and exposure paradigm, with experimental applications commonly including cell based assays of protein stability, oxidative injury, and inflammatory mediator output, as well as animal studies of lens opacification progression and tissue stress phenotypes, and in all cases the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives within biomedical research and drug discovery workflows.